Login / Signup

Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey.

Rehab MagdyDiana KhedrOsama YacoubAbeer AttiaMona A AbdelrahmanDoaa Mekkawy
Published in: Headache (2022)
Recipients of the COVID-19 vaccine should be counseled that they may experience headaches, especially after the adenoviral vector type. However, the intensity of such headache is mild to moderate and can resolve within a few days. Based on the current study design and the potential recall bias, these results may not be generalizable and should be preliminary.
Keyphrases
  • coronavirus disease
  • sars cov
  • respiratory syndrome coronavirus
  • high intensity
  • cross sectional
  • risk assessment